Letter to the Shareholders – November 2018
We would like to use this opportunity to inform you that we have now started the human clinical safety trial in UK and the first patients are now enrolled…
Letter to the Shareholders – June 2018
We are very pleased to announce that we late yesterday received the permission from MHRA (UK health authorities) to start the CE mark human trial…
General meeting Biovotec AS 2018
General meeting Biovotec AS 2018…
Letter to the Shareholders – March 2018
We are pleased to inform that we have now received another MNOK 10,0 (tranche 2 of 3 tranches) from the investor consortium that joined us last fall…
Biovotec AS completes planned placement of NOK 5 Million
Biovotec AS completes planned placement of NOK…
Annual General Meeting – May 2017
Minutes of the annual general meeting of Biovotec AS…